USA News Group News CommentaryIssued on behalf of GT Biopharma, Inc.VANCOUVER, Oct. 17, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development accelerates across oncology as companies advance novel mechanisms targeting previously difficult populations, with recent clinical data demonstrating high response rates in molecularly defined patient subgroups while FDA priority reviews compress development timelines for innovative platforms1. Multi-cancer early detection blood tests have correctly identify two thirds of cancers with a single blood draw and pinpoint the original cancer site in 85% of cases, detecting over 50 cancer types including 47 that lack recommended screening today while simplifying diagnosis processes that traditionally require expensive tests or invasive biopsies2. This convergence of targeted protein degraders, early detection diagnostics, immune activation platforms, and bispecific antibodies positions GT Biopharma, Inc. (NASDAQ:GTBP), Nurix Therapeutics, Inc. (NASDAQ:NRIX), GRAIL, Inc. (NASDAQ:GRAL), C4 Therapeutics, Inc. (NASDAQ:CCCC), and Pfizer, Inc. (NYSE:PFE). According to Precedence Research, the global precision oncology market reached $133 billion in 2025 and is predicted to surpass $312 billion by 2034, driven by increasing cancer prevalence and continuous advancement in genomic profiling techniques allowing more accurate and personalized therapies3. Regulatory agencies increasingly approve therapies for earlier disease stages while expanding patient populations through label expansions, creating favorable conditions for companies developing targeted degraders eliminating undruggable proteins, blood tests enabling intervention before symptoms appear, and combination strategies pairing novel mechanisms with established immunotherapy platforms4.GT Biopharma, Inc. (NASDAQ:GTBP) is a clinical-stage biotechnology company headquartered in San Francisco that's focused on harnessing the power of the immune system to fight cancer. The firm is currently advancing innovative immunotherapy treatments designed to combat some of the most challenging cancer types, with recent progress showing promise in its ongoing Phase 1 clinical trial of GTB-3650. The company has successfully enrolled both patients in the trial's third dosing group (Cohort 3), with neither patient experiencing concerning side effects or dose-limiting toxicities thus far. GT Biopharma expects to commence treatment for Cohort 4 patients before the end of 2025, with further data releases planned for early 2026.The Phase 1 study is testing GTB-3650 in patients battling relapsed or refractory blood cancers that express the CD33 protein, specifically acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These represent some of the most difficult cancer cases to treat, involving patients whose disease either came back after initial therapy or never responded to conventional treatment options.GTB-3650 works by stimulating the patient's natural killer cells, a type of immune cell that naturally hunts down and destroys abnormal cells, to specifically target cancer cells. Patients receive the therapy through continuous infusions following a structured schedule: two weeks of treatment followed by two weeks of rest, repeating this cycle for up to four months based on how they respond.After thorough safety assessments, the company successfully advanced into Cohort 3 following formal reviews of the initial two patient cohorts that found no safety or tolerability issues. The early results are particularly encouraging ...Full story available on Benzinga.com